HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: Belinostat, the third approved HDAC inhibitor, is used in peripheral T cell lymphoma (PTCL) treatment, while Panobinostat was the fourth HDAC inhibitor approved for treating multiple myeloma.